Discover Syndax’s Q3 2025 growth with Revuforj and Niktimvo, FDA approval, expanding markets, and robust financials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback